

Design, Synthesis, and Antimicrobial Activity of 6-O-Substituted Ketolides Active against Resistant Respiratory Tract Pathogens

Yat Sun Or, Richard F. Clark, Sanyi Wang,
Daniel T. W. Chu, Angela M. Nilus,
Robert K. Flamm, Michael Mitten, Patty Ewing,
Jeff Alder, and Zhenkun Ma*


Infectious Disease Research, Abbott Laboratories,
200 Abbott Park Road, Abbott Park, Illinois 60064-3537

Received December 20, 1999

Introduction. Bacterial resistance to antibiotic treatment has become a global health problem at the turn of the millennium.¹ Resistance occurs not only in hospitals² but also in certain community-acquired pathogens, particularly among the major respiratory tract pathogens.³ A 1997 multicenter surveillance study in the United States and Canada indicated that 43.8% of *Streptococcus pneumoniae* clinical isolates were intermediately or highly resistant to penicillin, a steady increase since the 1980s when only 3.8% of isolates were reported to be resistant to the same drug.⁴ These penicillin-resistant *S. pneumoniae* isolates also showed multiple resistance to other β -lactams, chloramphenicol, sulfonamides, tetracyclines, and macrolides. The same study revealed that in 1997, 33.5% of *Haemophilus influenzae* and 92.2% of *Moraxella catarrhalis* clinical isolates were found to be β -lactamase positive.⁵ ABT-773 is a member of a new generation of macrolide antibiotics which effectively addresses the drug-resistance problems associated with the treatment of respiratory tract infections.

The first macrolide, erythromycin, was introduced in the 1950s as a safe and effective agent. It is widely prescribed to patients with allergic reactions to penicillin. The major problem associated with erythromycin is its acid instability, leading to the formation of a 6,9-hemiketal and consequential degradation products which are directly responsible for its poor pharmacokinetic profile and gastrointestinal (GI) side effects.⁶ To address these problems, new macrolides such as clarithromycin and azithromycin were introduced in late 1980s. These agents effectively prevent the formation of 6,9-hemiketal degradation products, resulting in improved pharmacokinetics and better GI tolerability.⁷ The recent development of macrolide resistance among respiratory tract pathogens has, however, spurred further research aimed at the discovery of a next generation macrolide which can address the resistance issue and other deficiencies of current agents.⁸ In 1995, a novel series of macrolides, known as ketolides, was introduced. These compounds exhibited excellent activity against several types of macrolide-resistant organisms.⁹ In this communication, we wish to report the design, synthesis, and antibacterial activity of ABT-773, a novel ketolide having potent activity against multidrug-resistant respiratory tract

pathogens and excellent in vivo efficacy in experimental animal infection models. A full account of this work with a detailed study of the synthesis, structure–activity relationships, mechanism of action, and pharmacokinetic profiles will be published at a future date.



Design Rationale. Structural modification of existing antibiotics remains one of the most effective approaches for overcoming bacterial resistance.¹⁰ We focused our efforts on the modification of erythromycin, a safe and effective macrolide antibiotic with a well-defined mechanism of action and resistance mechanism.¹¹ Several earlier series of macrolides have made important contributions to our drug design strategy. In 1989, a series of aryl-substituted 11,12-cyclic carbamate macrolides, exemplified by A-66321, was reported by Abbott Laboratories. Several analogues of this series exhibited moderate activity against *S. pyogenes* with inducible and constitutive types of macrolides—lincosamides—streptogramin B (MLS_B) resistance.¹² In 1995, a series of aryl-substituted 11,12-cyclic carbamate ketolides, exemplified by RU-004, was reported by Hoechst Marion Roussel, which possessed potent activity against MLS_B-resistant *S. pneumoniae* and improved activity against *H. influenzae*.⁹ Telithromycin, a close analogue of RU-004, is currently under clinical development by Hoechst-Marion-Roussel.¹³ Also in 1995, Taisho reported a tricyclic ketolide series, exemplified by TE-802, which demonstrated activity against some erythromycin-resistant organisms.¹⁴ Both RU-004 and TE-802 showed excellent acid stability due to the removal of the acid-labile cladinose group. The structure–activity relationships (SARs) of these macrolide derivatives led us to believe that the aryl groups attached to the lactone ring are essential for overcoming MLS_B resistance, while the 3-keto group is important for overcoming efflux resistance.

To develop new macrolides with activity against such resistance, we sought to incorporate two key structural features into the molecules: an aryl group appropriately attached to the lactone ring and a keto group at the C-3 position. Both crystal and solution conformations of A-66321 and RU-004 indicated that the aryl groups in

* Corresponding author. Tel: 847-937-7015. Fax: 847-938-3403.
E-mail: zhenkun.ma@abbott.com.




Figure 1. Superimposed minimized solution conformations of ABT-773 (green) and RU-004 (black).

these molecules were positioned on the top, hydrophilic face of the macrolide ring, where the majority of oxygen-containing groups are localized.¹⁵ Since the C-6 hydroxy group of erythromycin is also located on the hydrophilic face of the macrolide ring, we felt that this position represented an ideal point for aryl group attachment. Our conformational analysis indicated that an aryl group tethered to the 6-O position would position itself in a similar spatial area with the aryl groups in A-66321 and RU-004. This relationship can be better illustrated by the superimposed conformations of ABT-773 and RU-004 (Figure 1).

Synthesis. The introduction of a versatile functional group at the sterically hindered C-6 hydroxy position became our first synthetic challenge. Previously, a methyl group had been successfully introduced at this position leading to the discovery of clarithromycin. However, attempts to introduce alkyl groups other than a methyl group proved to be impractical due to steric hindrance.¹⁶ We decided to take a more convergent approach by introducing an allyl group followed by further derivatization.


As indicated in Scheme 1, 6-*O*-allylerythromycin (**2**) was synthesized in an analogous fashion to the pre-

paration of 6-*O*-methylerythromycin (clarithromycin).¹⁷ Erythromycin was first protected as 9-ketaloxime 2',4''-bis(trimethylsilyl)erythromycin (**1**). Treatment of **1** with allyl bromide and potassium hydroxide (KOH), in a mixture of dimethyl sulfoxide (DMSO) and tetrahydrofuran (THF), provided a low conversion of starting material. We soon realized that the low conversion was due to a competing reaction between allyl bromide and KOH. Potassium *tert*-butoxide (KO^{*t*}Bu), a sterically hindered base, was thus employed to minimize the undesired side reaction. This modification brought the reaction to more than 90% conversion.¹⁸ Sequential deprotection of the trimethylsilyl (TMS) and ketal groups followed by deoxygenation provided 6-*O*-allylerythromycin (**2**) in 31% overall yield from erythromycin.

The 3-keto group was introduced in three steps from 6-*O*-allylerythromycin,¹⁹ beginning with the acidic hydrolysis of the cladinose sugar. The 2'-OH was then protected as an acetyl ester. Finally, Corey–Kim oxidation²⁰ of the 3-OH provided the 6-*O*-allyl ketolide **3** in 77% overall yield from **2**. Introduction of an aryl group to the allyl side chain of **3** was achieved by utilizing a Heck coupling reaction.²¹ Under optimized conditions (Pd(OAc)₂/P(*o*-tolyl)₃/Et₃N/CH₃CN), various *trans*-6-*O*-arylallyl ketolides **4** were obtained in good yields after deprotection (Scheme 1).²²

Conversion of **3** to the corresponding 11,12-cyclic carbamate **6** was achieved in two steps, proceeding through an acylimidazole intermediate **8** (Scheme 2). Thus, when **3** was treated with lithium hydride (LiH) in the presence of *N,N*-carbonyldiimidazole (CDI) for a period of 7 days, **8** was obtained in good yield. This transformation has been known to proceed through a 11,12-cyclic carbonate intermediate.²³ Base-catalyzed elimination at the 10,11-position, followed by acylation of the free 12-OH, provided acylimidazole **8**. Subsequent reaction of **8** with aqueous ammonia provided **6** as the

Scheme 1^a




^a Conditions: (a) (1) allyl bromide, KO^{*t*}Bu, DMSO–THF, (2) HOAc, H₂O–CH₃CN, (3) NaHSO₃/HCO₂H, EtOH–H₂O, 33% in 3 steps; (b) (1) HCl, EtOH, (2) Ac₂O, Et₃N, CH₂Cl₂, (3) NCS, Me₂S, Et₃N, CH₂Cl₂, 77% in 3 steps; (c) (1) Ar-X, Pd(OAc)₂, P(*o*-tolyl)₃, Et₃N, CH₃CN, (2) MeOH, 60–85% in 2 steps; (d) (1) LiH, CDI, THF, (2) aq NH₃ (28%), CH₃CN–THF, 60% in 2 steps; (e) (1) Ac₂O, Et₃N, DMAP, CH₂Cl₂, (2) NaN(TMS)₂, CDI, THF–DMF, (3) aq NH₃ (28%), CH₃CN–THF, 78% in 3 steps; (f) (1) HCl, EtOH, (2) NCS, Me₂S, Et₃N, CH₂Cl₂, 80% in 2 steps.

Table 1. In Vitro Antibacterial Activity of Selected Compounds (MIC, $\mu\text{g/mL}$)

strain	compound (Ar group)						Teli	Ery
	4a (H)	4b (Ph)	4c (3-quinolyl)	7a (H)	7b (Ph)	7c (3-quinolyl)		
<i>S. aureus</i> ATCC 6538P	12.5	1.56	0.2	0.78	0.1	0.05	0.1	0.2
<i>S. aureus</i> A 5177	50	1.56	0.2	1.56	0.1	0.05	0.1	6.2
<i>S. aureus</i> A 5278	>100	>100	>100	>100	>100	>100	>100	>100
<i>S. pyogenes</i> EES 61	—	0.25	0.2	0.25	0.03	0.004	0.004	0.06
<i>S. pyogenes</i> 930	>128	64	100	>64	64	1	8	>128
<i>S. pyogenes</i> PIU 2548	32	2	0.1	2	0.25	0.125	2	32
<i>S. pneumoniae</i> ATCC 6303	4	0.25	0.03	0.5	0.03	0.004	0.004	0.06
<i>S. pneumoniae</i> 5737	>128	64	16	>64	64	0.25	8	>128
<i>S. pneumoniae</i> 5649	8	2	0.25	0.25	0.25	0.25	0.5	16
<i>H. influenzae</i> DILL	>128	128	16	64	4	2	2	8

major product and its 10-epimer as a minor product in a 2:1 ratio.

Scheme 2



Alternatively, **6** was obtained through another route starting from **2**. After protection of the 2'- and 4''-OH groups, the diacetate was converted to the acylimidazole intermediate **8** (Scheme 2), which was further reacted with aqueous ammonia to give **5** in 78% overall yield from **2**. In this case the reaction was more selective, producing less than 10% of the 10-epimer of **5**. Subsequent hydrolysis of the C-3 cladinose and Corey–Kim oxidation²⁰ of the resulting 3-OH compound provided **6** in 80% yield over two steps. Finally, aryl groups were introduced to **6** under Heck coupling conditions²¹ as stated above to give, after deprotection, *trans*-6-*O*-arylallyl ketolides **7** in excellent yields.

In Vitro Antibacterial Activity. The 6-*O*-substituted ketolides and the reference agents telithromycin and erythromycin were tested against a panel of representative respiratory pathogens selected from the Abbott clinical culture collection. Various macrolide- and multidrug-resistant isolates were included in these tests in order to identify potent analogues that could overcome macrolide resistance. *Staphylococcus aureus* ATCC 6538P, *Streptococcus pyogenes* EES 61, and *Streptococcus pneumoniae* ATCC 6303 are erythromycin-susceptible strains. *S. aureus* A 5177 is an inducibly MLS_B-resistant strain encoded by an *ermA* gene. *S. aureus* A 5278 is a constitutively MLS_B-resistant strain also encoded by an *ermA* gene. *S. pyogenes* 930 and *S. pneumoniae* 5737 are MLS_B-resistant strains encoded by *ermB* gene. *S. pyogenes* PIU 2548 and *S. pneumoniae* 5649 are efflux-resistant strains encoded by *mefA* and *mefE* genes, respectively. *Haemophilus influenzae* DILL is an ampicillin-resistant strain with a β -lactamase-positive determinant. The in vitro antibacterial activities are reported as minimum inhibitory concentrations (MICs), which were determined by the agar dilution method as recommended by the National Committee for Clinical Laboratory Standards. The in vitro antibacterial activities of a selected group of 6-*O*-substituted ketolides and reference compounds are shown in Table 1.

The 6-*O*-allyl ketolide **4a** showed weak antibacterial activity. However, the corresponding 6-*O*-phenylallyl analogue **4b** and the 6-*O*-quinolylallyl analogue **4c** exhibited significantly improved activity. A similar trend was observed when an aryl group was introduced to the 6-*O*-allyl-11,12-carbamate ketolide **7a**. Compounds **7b** and **7c** showed much better antibacterial activity than **7a** against both susceptible and resistant organisms. The structures of the aryl groups in these analogues also had profound effects on the antibacterial activities. The quinolyl analogues (**4c** and **7c**), for example, demonstrated further improved activity when compared to their phenyl counterparts (**4b** and **7b**). In addition, the 11,12-cyclic carbamate group was an important contributor to the antibacterial activity. Compounds **7a**, **7b**, and **7c** exhibited more than 10-fold improved activity as compared to the corresponding 11,12-diols **4a**, **4b**, and **4c**.

Compound **7c** was designated as ABT-773 and is currently under clinical studies. Compared with erythromycin, ABT-773 exhibited significantly improved activity against erythromycin-susceptible strains. It showed excellent activity against both inducible and efflux-resistant organisms, while erythromycin was only weakly active. It also exhibited potent activity against MLS_B-resistant *S. pyogenes* and *S. pneumoniae* which were highly resistant to erythromycin. In addition, it showed 4-fold improvement in MIC against ampicillin-resistant *H. influenzae*. Compared with reference ketolide telithromycin, ABT-773 demonstrated improved activity against both efflux- and MLS_B-resistant bacteria. However, none of the new ketolides, including ABT-773 and telithromycin, showed any activity against MLS_B constitutively resistant *S. aureus*.

In Vivo Efficacy. The in vivo efficacies of ABT-773 and reference compounds azithromycin and telithromycin were assessed by mouse protection tests and rat lung infection models. In the mouse protection tests, the mice were inoculated intravenously with a 100-fold LD₅₀ of representative organisms. Test compounds were administered by oral gavage at 1 and 5 h post-inoculation. Mortality rates of the mice were monitored for a period of 7 days post-inoculation with a 100% mortality rate for untreated controls. The efficacy of each compound, based on the survival rates over a dose range, was reported as the drug dose resulting in a survival of 50% of treated mice over the duration of the trial (ED₅₀). In the rat lung infection models, the rats were intratracheally inoculated with 0.5 mL of a bacteria suspension in 5% gastric hog mucin containing log 10⁶–10⁸ cfu. Test compounds were administered by peroral gavage once

Table 2. In Vivo Efficacy of Selected Compounds in the Mouse Protection Tests (ED₅₀, mg/kg)

compd	<i>S. aureus</i> 10649 ^a		<i>S. pneumoniae</i> 6303 ^a		<i>S. pyogenes</i> C203 ^a	
	MIC (μg/mL)	ED ₅₀ (95% CL)	MIC (μg/mL)	ED ₅₀ (95% CL)	MIC (μg/mL)	ED ₅₀ (95% CL)
ABT-773	0.05	10.4 (7–15)	0.004	12.5 (10–16)	0.002	2.5 (2–4)
Teli	0.1	12.5 (8–20)	0.004	34.1 (21–57)	—	—
Azi	0.78	24.8 (18–37)	0.12	18.8 (10–34)	0.06	6.1 (4–9)

^a *S. aureus* 10649, *S. pyogenes* C203, and *S. pneumoniae* 6303 are erythromycin-susceptible strains. CL, confidence limits.

Table 3. In Vivo Efficacy of Selected Compounds in Rat Lung Infection Models (ED₅₀, mg/kg/day)

compd	<i>S. pneumoniae</i> 6303 ^a		<i>S. pneumoniae</i> 5649 ^a		<i>S. pneumoniae</i> 6396 ^a	
	MIC (μg/mL)	ED ₅₀ (95% CL)	MIC (μg/mL)	ED ₅₀ (95% CL)	MIC (μg/mL)	ED ₅₀ (95% CL)
ABT-773	0.004	<0.63	0.25	7.0 (6.9–7.1)	0.015	1.6 (1.3–2.2)
Teli	0.004	2.3 (2.1–2.5)	0.5	25.8 (9.3–72)	0.125	26.7 (21–34)
Azi	0.12	6.0 (3.8–9.6)	16	78.7 (62–99)	>128	>100

^a *S. pneumoniae* 6303 is an erythromycin-susceptible strain, *S. pneumoniae* 5649 is an efflux-resistant strain, and *S. pneumoniae* 6396 is a MLS_B-resistant strain. CL, confidence limits.

daily, days 1–3, starting 18 h post-inoculation. Lung bacterial burden was assessed from serial dilution plating of lung tissue homogenates on day 4. The ED₅₀ to yield a 2 log reduction in bacteria count compared to vehicle-treated infected controls was calculated from the group means using linear regression. The efficacy of ABT-773 and reference compounds is shown in Tables 2 and 3.

In the mouse protection tests ABT-773 demonstrated improved efficacy against macrolide-susceptible strains as compared to reference macrolide azithromycin and reference ketolide telithromycin. In the rat lung infection models, ABT-773 exhibited superior efficacy against various *S. pneumoniae* strains. ABT-773 showed substantially better efficacy than both telithromycin and azithromycin against a macrolide-susceptible strain, *S. pneumoniae* 6303. Against infections caused by an efflux-resistant strain, *S. pneumoniae* 5649, ABT-773 exhibited a 3-fold improvement in efficacy over telithromycin and a 10-fold improvement over azithromycin. Against infections caused by an MLS_B-resistant strain, *S. pneumoniae* 6396, ABT-773 demonstrated excellent efficacy, while telithromycin showed weaker efficacy and azithromycin gave no efficacy under a 100 mg/kg/day dose.

Conclusion. A novel series of 6-O-substituted ketolides having activity against both MLS_B- and efflux-resistant bacteria was designed and synthesized. SAR studies led to the discovery of a potent antibacterial agent, ABT-773. ABT-773 exhibited excellent activities against all the key respiratory tract pathogens, including those resistant to macrolides and other antibiotics. It was highly active against the two major types of resistance: MLS_B resistance encoded by *erm* genes and efflux resistance encoded by *mef* genes. ABT-773 demonstrated excellent efficacies against various infections in experimental animal models. It showed improved efficacy against infections caused by macrolide-susceptible bacteria as compared to reference macrolide azithromycin and reference ketolide telithromycin. ABT-773 provided excellent efficacy against infections caused by macrolide-resistant bacteria, while telithromycin showed

weaker efficacy and azithromycin showed weaker or no efficacy against such infections.

Acknowledgment. The authors acknowledge the support of Abbott Process Research Department for providing research intermediates, Structural Chemistry Department for structural characterization, and Clinical Microbiology Department for in vitro and in vivo testing.

References

- (1) (a) Bax, R. P.; Anderson, R.; Crew, J.; Fletcher, P.; Johnson, T.; Kaplan, E.; Knaus, B.; Kristinsson, K.; Malek, M.; Strandberg, L. Antibiotic Resistance-What Can We Do? *Nature Med.* **1998**, *4*, 545–546. (b) Baquero, F. Gram-Positive Resistance: Challenge for the Development of New Antibiotics. *J. Antimicrob. Chemother.* **1997**, *39*, Suppl. A, 1–6.
- (2) Schentag, J. J.; Hyatt, J. M.; Carr, J. R.; Paladino, J. A.; Birmingham, M. C.; Zimmer, G. S.; Cumbo, T. J. Genesis of Methicillin-Resistant *Staphylococcus aureus* (MRSA), How Treatment of MRSA Infections Has Selected for Vancomycin-Resistant *Enterococcus faecium*, and the Importance of Antibiotic Management and Infection Control. *Clin. Infect. Dis.* **1998**, *26*, 1204–1214.
- (3) (a) Jacobs, M. R.; Bajaksouzian, S.; Zilles, A.; Lin, G.; Pankuch, G. A.; Appelbaum, P. C. Susceptibilities of *Streptococcus pneumoniae* and *Haemophilus influenzae* to 10 Oral Antimicrobial Agents Based on Pharmacodynamic Parameters: 1997 U.S. Surveillance Study. *Antimicrob. Agents Chemother.* **1999**, *43*, 1901–1908. (b) Thornberry, C.; Ogilvie, P. T.; Holley, H. P.; Sahm, D. F. Survey of Susceptibilities of *Streptococcus pneumoniae*, *Haemophilus influenzae*, and *Moraxella catarrhalis* Isolates to 26 Antimicrobial Agents: a Prospective U.S. Study. *Antimicrob. Agents Chemother.* **1999**, *43*, 2612–2623. (c) Barry, A. L. Antimicrobial Resistance Among Clinical Isolates of *Streptococcus pneumoniae* in North America. *Am. J. Med.* **1999**, *107*, 28S–33S. (d) Tomasz, A. New Faces of an Old Pathogen: Emergence and Spread of Multidrug-Resistant *Streptococcus pneumoniae*. *Am. J. Med.* **1999**, *107*, 55S–59S.
- (4) Doern, G. V.; Pfaller, M. A.; Kugler, K.; Freeman, J.; Jones, R. N. Prevalence of Antimicrobial Resistance Among Respiratory Tract *Streptococcus pneumoniae* in North America: 1997 Results from the SENTRY Antimicrobial Surveillance Program. *Clin. Infect. Dis.* **1998**, *27*, 764–770.
- (5) Doern, G. V.; Jones, R. N.; Pfaller, M. A.; Kugler, K. THE SENTRY PARTICIPANTS GROUP. *Haemophilus influenzae* and *Moraxella catarrhalis* from Patients with Community-Acquired Respiratory Tract Infections: Antimicrobial Susceptibility Patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). *Antimicrob. Agents Chemother.* **1999**, *43*, 385–389.
- (6) Omura, S.; Tsuzuki, K.; Sunazuka, T.; Marui, S.; Toyoda, H.; Inatomi, N.; Itoh, Z. Macrolide with Gastrointestinal Motor Stimulating Activity. *J. Med. Chem.* **1987**, *30*, 1943–1948.
- (7) For reviews, see: (a) Chu, D. T. W. Recent Developments in 14- and 15-Membered Macrolides. *Exp. Opin. Invest. Drugs* **1995**, *4*, 65–94. (b) Bryskier, A.; Agouridas, C.; Gasc, J.-C. Classification of Macrolide Antibiotics. In *Macrolide*; Bryskier, A. J., Butzler, J.-P., Neu, H. C., Tulkens, P. M., Eds.; Arnette Blackwell: Paris, 1993; pp 5–66.
- (8) (a) Weisblum, B. Macrolide Resistance. *Drug Resistance Updates* **1998**, *1*, 29–41. (b) Amsden, G. W. Pneumococcal Macrolide Resistance-Myth or Reality. *J. Antimicrob. Chemother.* **1999**, *44*, 1–6. (c) Bryskier, A. Novelty in the Field of Macrolides. *Exp. Opin. Invest. Drugs* **1997**, *6*, 1697–1709. (d) Bryskier, A. New Research in Macrolides and Ketolides since 1997. *Exp. Opin. Invest. Drugs* **1999**, *8*, 1171–1194.
- (9) (a) Agouridas, C.; Benedetti, Y.; Denis, A.; Le Martret, O.; Chantot, J. F. Ketolides: A New Distinct Class of Macrolide Antibacterials. Synthesis and Structural Characterization of RU 004. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995; Abstr. No. F157. (b) Agouridas, C.; Denis, A.; Auger, J.; Benedetti, Y.; Bonnefoy, A.; Bretin, F.; Chantot, J.; Dussarat, A.; Fromentin, C.; D'Ambri-eres, S. G.; Lachaud, S.; Laurin, P.; Le Martret, O.; Loyau, V.; Tessot, N. Synthesis and Antibacterial Activity of Ketolides (6-O-Methyl-3-Oxoerythromycin Derivatives): A New Class of Antibacterials Highly Potent Against Macrolide Resistant and Susceptible Respiratory Pathogens. *J. Med. Chem.* **1998**, *41*, 4080–4100.
- (10) (a) Domagala, J. M.; Sanchez, J. P. New Approaches and Agents to Overcome Bacterial Resistance. *Annu. Rep. Med. Chem.* **1997**, *32*, 111–120. (b) Chopra, I.; Hodgson, J.; Metcalf, B.; Poste, G. The Search for Antimicrobial Agents Effective against Bacteria Resistant to Multiple Antibiotics. *Antimicrob. Agents Chemother.*

- 1997, 41, 479–503. (c) Coleman, K.; Athalye, M.; Clancey, A.; Davison, M.; Payne, D. J.; Perry, C. R.; Chopra, I. Bacterial Resistance Mechanism as Therapeutic Targets. *J. Antimicrob. Chemother.* **1994**, 33, 1091–1116.
- (11) See ref 8a and: (a) Nakajima, Y. Mechanism of Bacterial Resistance to Macrolide Antibiotics. *J. Infect. Chemother.* **1999**, 5, 61–74. (b) Hansen, L. H.; Mauvais, P.; Douthwaite, S. The Macrolide-Ketolide Antibiotic Binding Site Is Formed by Structures in Domain II and V of 23S Ribosomal RNA. *Mol. Microbiol.* **1999**, 31, 623–631. (c) Xiong, L.; Shah, S.; Mauvais, P.; Mankin, A. S. A Ketolide Resistance Mutation in Domain II of 23S rRNA Reveals the Proximity of Hairpin 35 to the Peptidyl Transferase Center. *Mol. Microbiol.* **1999**, 31, 633–639.
- (12) Fernandes, P. B.; Baker, W. R.; Freiberg, L. A.; Hardy, D. J.; McDonald E. J. New Macrolides Active against *Streptococcus pyogenes* with Inducible or Constitutive Type of Macrolide-Lincosamide-Streptogramin B Resistance. *Antimicrob. Agents Chemother.* **1989**, 33, 78–81.
- (13) Denis, A.; Agouridas, C.; Auger, J.-M.; Benedetti, Y.; Bonnefoy, A.; Bretin, F.; Chantot, J.-F.; Dussarat, A.; Fromentin, C.; D'Ambrieres, S. G.; Lachaud, S.; Laurin, P.; Martret, O. L.; Loyau, V.; Tessot, N.; Pejac, J.-M.; Perron, S. Synthesis and Antibacterial Activity of HMR 3647. A New Ketolide Highly Potent against Erythromycin-Resistant and Susceptible Pathogens. *Bioorg. Med. Chem. Lett.* **1999**, 9, 3075–3080.
- (14) Asaka, T.; Kashimura, M.; Misawa, Y.; Ono, T.; Suzuki, K.; Yoshida, T.; Akashi, T.; Yokoo, C.; Nagate, T.; Morimoto, S. A New Macrolide Antibiotics, TE-802: Synthesis and Biological Properties. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995; Abstr. No. F176.
- (15) See ref 9b for crystal structure of RU-004. For solution conformations of macrolides, see: (a) Awan, A.; Brennan, R. J.; Regan, A. C.; Barber, J. Conformational Analysis of the Erythromycin Analogues Azithromycin and Clarithromycin in Aqueous Solution and Bound to Bacterial Ribosomes. *J. Chem. Soc., Chem. Commun.* **1995**, 1653–1654. (b) Bertho, G.; Ladam, P.; Gharbi-Benarous, J.; Delaforge, M.; Girault, J.-P. Solution Conformation of Methylated Macrolide Antibiotics Roxithromycin and Erythromycin Using NMR and Molecular Modelling. Ribosome-Bound Conformation Determined by TRNOE and Formation of Cytochrome P450-Metabolite Complex. *Int. J. Biol. Macromol.* **1998**, 22, 103–127. (c) Bertho, G.; Gharbi-Benarous, J.; Delaforge, M.; Girault, J.-P. Transferred Nuclear Overhauser Effect Study of Macrolide-Ribosome Interactions: Correlation between Antibiotic Activities and Bound Conformations. *Bioorg. Med. Chem.* **1998**, 6, 209–221. (d) Bertho, G.; Gharbi-Benarous, J.; Delaforge, M.; Lang, C.; Parent, A.; Girault, J.-P. Conformational Analysis of Ketolide, Conformations of RU 004 in Solution and Bound to Bacterial Ribosomes. *J. Med. Chem.* **1998**, 41, 3373–3386.
- (16) For a summary of earlier work, see: Lartey, P. A.; Perun, T. J. Synthetic Modifications of the Erythromycin A Macrolactone: Effects on Biological Activity. In *Studies in Natural Products Chemistry*; Atta-ur-Rahman, Ed.; Elsevier Scientific Publishers: Amsterdam, 1993; Vol. 13, pp 155–185.
- (17) Morimoto, S.; Matsunaga, T.; Adachi, T.; Kashimura, M.; Asaka, T.; Sota, K.; Watanabe, Y.; Sekiuchi, K. Preparation of Erythromycin A Derivatives. European Patent EP 272110 A2, 1988.
- (18) Conditions for allylation step: KOBu^t (2.0 equiv) in DMSO/THF was added slowly over 4 h to an ice-cold solution of **1** and allyl bromide (2.0 equiv) in DMSO/THF with vigorous agitation. Crude product obtained after normal aqueous workup was carried to the next step without purification.
- (19) Or, Y. S.; Ma, Z.; Clark, R. F.; Chu, D. T.; Plattner, J. J.; Griesgraber, G. Preparation of 6-O-Substituted Erythromycin Ketolides as Antibacterial Agents. U.S. Patent US 5866549, 1998.
- (20) Corey, E. J.; Kim, C. U. New and Highly Effective Method for the Oxidation of Primary and Secondary Alcohols to Carbonyl Compounds. *J. Am. Chem. Soc.* **1972**, 94, 7586–7587.
- (21) Cabri, W.; Candiani, I. Recent Developments and New Perspectives in the Heck Reaction. *Acc. Chem. Res.* **1995**, 28, 2–7.
- (22) Heck coupling conditions: A solution of **3**, aryl halide (2 equiv), Pd(OAc)₂ (0.2 equiv), P(*o*-tolyl)₃ (0.3 equiv), Et₃N (3.0 equiv) in CH₃CN was degassed and sealed in a pressure tube. Reaction mixture was heated at 90 °C for 24 h, followed by a normal workup.
- (23) (a) Elliott, R. L.; Pireh, D.; Griesgraber, G.; Nilius, A. M.; Ewing, P. J.; Bui, M. H.; Raney, P. M.; Flamm, R. K.; Kim, K.; Henry, R. F.; Chu, D. T. W.; Plattner, J. J.; Or, Y. S. Anhydrolide Macrolides. 1. Synthesis and Antibacterial Activity of 2,3-Anhydro-6-*O*-Methyl 11,12-Carbamate Erythromycin A Analogues. *J. Med. Chem.* **1998**, 41, 1651–1659. (b) Griesgraber, G.; Kramer, M. J.; Elliott, R. L.; Nilius, A. M.; Ewing, P. J.; Raney, P. M.; Bui, M.-H.; Flamm, R. K.; Chu, D. T. W.; Plattner, J. J.; Or, Y. S. Anhydrolide Macrolides. 2. Synthesis and Antibacterial Activity of 2,3-Anhydro-6-*O*-Methyl 11,12-Carbamate Erythromycin A Analogues. *J. Med. Chem.* **1998**, 41, 1660–1670.

JM990618N